2. Academic Validation
  3. Glutaminase isoenzymes in the metabolic therapy of cancer

Glutaminase isoenzymes in the metabolic therapy of cancer

  • Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):158-164. doi: 10.1016/j.bbcan.2018.07.007.
José M Matés 1,  José A Campos-Sandoval 2,  Javier Márquez 2
Affiliations

Affiliations

  • 1 IBIMA, Department of Molecular Biology and Biochemistry, Faculty of Sciences, Campus de Teatinos, University of Málaga, 29071 Málaga, Spain. Electronic address: jmates@uma.es.
  • 2 IBIMA, Department of Molecular Biology and Biochemistry, Faculty of Sciences, Campus de Teatinos, University of Málaga, 29071 Málaga, Spain.
PMID: 30053497 DOI: 10.1016/j.bbcan.2018.07.007
Abstract

Altered cellular metabolism is a hallmark of Cancer. Cancer cells express isoforms of metabolic Enzymes that may constitute therapeutic targets. Glutaminase controls glutamine metabolism and their expression correlate with malignancy of tumours. The two types of Glutaminase isoenzymes, GLS and GLS2, differ in their expression patterns and functional roles: GLS has oncogenic properties and GLS2 has been described as a tumour suppressor factor. Selective genomic and epigenomic intervention over Glutaminase affects the metabolic reprogramming of Cancer. This review highlights the molecular metabolic vulnerabilities in various types of Cancer, to be used for biomarker development, drug design, and in personalized oncology.

Keywords

Cancer metabolism; Combinatory therapy; Glutaminase inhibitors; Glutaminase isoenzymes; Glutamine; Metabolic reprogramming.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z